SRPK1: A cisplatin sensitive protein expressed in retinoblastoma
SRPK1: A cisplatin sensitive protein expressed in retinoblastoma
复制标题
DOI：
10.1002/pbc.21088
复制
发表时间：
2008-02-01
影响因子：
3.2
通讯作者：
Das, Radha R.
中科院分区：
文献类型：
--
作者：
Krishnakumar, Subramanian;Mohan, Adithi;Das, Radha R.
化疗是治疗视网膜母细胞瘤（RB）的重要方法。哺乳动物富含丝氨酸/精氨酸的蛋白特异性激酶 1 (SRPK1) 是一种顺铂敏感性相关蛋白，已知其下调与对顺铂和卡铂的反应降低有关。我们研究了 63 个存档 RB 中 SRPK1 的表达，并将其表达与病理分期和化疗暴露相关联。根据新的眼内 RB 国际分类，大多数 RB (62/63) 处于晚期（D 组和 E 组），具有中度至高度治疗失败的风险，并且 32/62 (51%) 肿瘤中 SRPK1 降低。 SRPK1 蛋白表达在眼眶复发或转移的 (100%) 8/8 RB 中降低。 SRPK1 蛋白表达在 RB 中随病情进展而降低，这可能会增加 RB 的耐药机制。
Chemotherapy is an essential modality in the treatment of retinoblastoma (RB). Mammalian serine/arginine-rich protein-specific kinase 1 (SRPK1) is a cisplatin-sensitivity-related protein and its downregulation is known to be associated with decreased response to cisplatin and carboplatin. We investigated the expression of SRPK1 in 63 archival RB and correlated its expression with pathologic staging and exposure to chemotherapy. The majority of the RB (62/63) were advanced stage (Groups D and E) with intermediate to high risk of treatment failure according to the new international classification for intraocular RB and SRPK1 was reduced in 32/62 (51%) tumors. SRPK1 protein expression was reduced in (100%) 8/8 RB that had recurred in the orbit or had metastasized. SRPK1 protein expression is reduced in RB with advanced stage of presentation and this may add to drug resistance mechanisms in RB.